$19.64
+0.37 (+1.92%)
Open$19.27
Previous Close$19.27
Day High$20.00
Day Low$19.01
52W High$44.60
52W Low$8.51
Volume—
Avg Volume554.7K
Market Cap1.12B
P/E Ratio—
EPS$-7.80
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+50.3% upside
Current
$19.64
$19.64
Target
$29.51
$29.51
$22.12
$29.51 avg
$35.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.95M | 140.52M | 130.81M |
| Net Income | -489,249,313 | -116,113 | -126,311 |
| Profit Margin | -3,777.4% | -0.1% | -0.1% |
| EBITDA | -495,529,465 | -178,287 | -168,053 |
| Free Cash Flow | — | -139,366 | -118,293 |
| Rev Growth | — | -3.7% | +16.0% |
| Debt/Equity | 0.32 | 0.89 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |